Evotec SE (EVT) Stock Price & News

Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development. The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more. On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia

About Evotec SE

CEO-

Employees4,46 հզր

Founded1993

Headquarters-

Sector-

Websiteevotec.com

All values in EUR	2025 թ. սեպ	2025 թ. դեկ	2026 թ. մրտ	2026 թ. հնս
Revenue	163,89 մլն	253,27 մլն	156,64 մլն	143,48 մլն
Cost of goods sold	163,95 մլն	174,81 մլն	158,21 մլն	145,06 մլն
Cost of revenue	163,95 մլն	174,81 մլն	158,21 մլն	145,06 մլն
Research and development expenses	8,71 մլն	9,83 մլն	10,08 մլն	10,26 մլն
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	42,31 մլն	44,35 մլն	43,79 մլն	39,29 մլն
Operating expense	43,53 մլն	55,25 մլն	44,85 մլն	87,74 մլն
Total operating expenses	207,48 մլն	230,06 մլն	203,07 մլն	232,80 մլն
Operating income	-43,59 մլն	23,21 մլն	-46,42 մլն	-89,32 մլն
Other non operating income	1,19 մլն	-33,96 մլն	1,89 մլն	-839,00 հզր
EBT including unusual items	-42,96 մլն	29,46 մլն	-122,18 մլն	-48,12 մլն
EBT excluding unusual items	-43,36 մլն	18,35 մլն	-47,40 մլն	-94,00 մլն
Income tax expense	127,00 հզր	14,84 մլն	-244,00 հզր	-1,47 մլն
Effective tax rate	-0,30%	50,37%	0,20%	3,06%
Other operating expenses	-7,50 մլն	1,07 մլն	-9,02 մլն	38,20 մլն
Net income	-43,09 մլն	14,62 մլն	-121,94 մլն	-46,65 մլն
Net profit margin	-26,29%	5,77%	-77,84%	-32,51%
Earnings per share	-0,24	-	-	-
Interest and investment income	841,00 հզր	11,84 մլն	-	-
Interest expense	-2,28 մլն	-	-2,58 մլն	-2,97 մլն
Net interest expenses	-1,44 մլն	11,84 մլն	-2,58 մլն	-2,97 մլն
Depreciation and amortization charges	-	-	-	-
EBITDA	-18,27 մլն	41,91 մլն	-22,60 մլն	-64,88 մլն
Gain or loss from assets sale	-	-	-	-

Finance

Ask anything